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Leveraging existing data sets
to generate new insights into
Alzheimer’s disease biology in
specific patient subsets
Kevin D. Fowler1,*, Jason M. Funt1,*, Maxim N. Artyomov1,2, Benjamin Zeskind1,
Sarah E. Kolitz1,* & Fadi Towfic1,*
To generate new insights into the biology of Alzheimer’s Disease (AD), we developed methods
to combine and reuse a wide variety of existing data sets in new ways. We first identified genes
consistently associated with AD in each of four separate expression studies, and confirmed this
result using a fifth study. We next developed algorithms to search hundreds of thousands of Gene
Expression Omnibus (GEO) data sets, identifying a link between an AD-associated gene (NEUROD6)
and gender. We therefore stratified patients by gender along with APOE4 status, and analyzed
multiple SNP data sets to identify variants associated with AD. SNPs in either the region of
NEUROD6 or SNAP25 were significantly associated with AD, in APOE4+ females and APOE4+ males,
respectively. We developed algorithms to search Connectivity Map (CMAP) data for medicines that
modulate AD-associated genes, identifying hypotheses that warrant further investigation for treating
specific AD patient subsets. In contrast to other methods, this approach focused on integrating
multiple gene expression datasets across platforms in order to achieve a robust intersection of
disease-affected genes, and then leveraging these results in combination with genetic studies in
order to prioritize potential genes for targeted therapy.

In recent years, many investigators have thoughtfully applied genetics and genomics approaches to investigate the biology of Alzheimer’s Disease (AD)1–3. These efforts have yielded a rich collection of gene
expression and single-nucleotide polymorphism (SNP) data sets, along with extensive analyses of particular data sets. The availability of such studies provides the opportunity to generate fresh insights into
the biology of AD, independently of prevailing hypotheses, by integrating existing data sets in novel and
innovative ways.
A number of studies have examined ways to do this. For example, Krauthammer et al. used seed genes
of known importance in AD to identify additional candidate genes using genetic linkage and text-mined
protein-protein interaction data via a graph-theoretic method4. Chen et al. reported a method to rank
AD-related genes by importance based on database protein-protein interaction data5. Liu and colleagues
interpreted genomic and proteomic data using a Bayesian statistical framework with the aim of prioritizing candidate genes, and found that this approach was able to identify known candidate genes for
Alzheimer’s6. Soler-López et al. utilized an initial list of known AD genes to identify additional genes of
interest based on combining protein-protein interaction data with criteria of AD- associated genomic
locations or changes in gene expression7. Caberlotto et al. obtained a list of seed genes from a gene
expression dataset, SNP data, as well as genes previously identified as potential AD drug targets, and
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Figure 1. Genes downregulated in AD consistently across 5 data sets. (a) Venn diagram illustrating the
intersection of significantly downregulated genes across multiple data sets. (b) Box plots of NEUROD6
expression in each of the 5 data sets. (c) Heat map of the 24 consistently downregulated genes showing
specificity for brain tissue.

used database protein-protein interaction data to investigate potential underlying biology represented
among these genes8.
These methods all utilized protein-protein interaction data to help predict which genes might be
important in disease. By contrast, the approach reported here uses intersections across multiple datasets
to filter for more robust candidate genes, obtaining an intersection of genes from expression datasets that
enables targeted mining of SNP data to identify those candidate genes more likely to be causal.
Methodologies for combining heterogeneous data sets to identify robust biological signals are not well
established, particularly in the area of integrating gene expression and SNP data from separate cohorts.
Differentially expressed genes alone are of limited utility, since they include both downstream signals
resulting from disease pathology and upstream signals that may be more causative. Incorporating SNP
signals into an analysis can help identify causative signals that may represent more direct targets for new
medicines.
In conducting such integrative analyses, it is also critical to consider patient stratification. Today,
studies of many different diseases are increasingly finding subsets of patients with distinct patterns of
biology9,10. It is plausible that not all AD patients have identical mechanisms driving their common
symptoms and manifestations of the disease. To the extent that AD patients may differ in certain aspects
of the biology underlying their disease, it stands to reason that certain medicines may be more, or less,
effective in particular subsets of patients.
Therefore, we sought to integrate publicly available gene expression and SNP data sets as a means to
generate new insights into the biology of AD, stratify these patients, and generate hypotheses for new
subset-specific medicines.

Results

Differential expression analysis between AD patients and healthy controls. We first per-

formed an integrated analysis of existing Alzheimer’s gene expression data sets. We identified genes with
significantly differing expression levels between healthy controls and AD patients (as defined by overall
diagnosis or NFT score) in each of four data sets. Taking the intersection, 25 genes were downregulated
significantly with disease in all four data sets. We subsequently obtained a fifth data set (Zhang et al.),
and observed that in this study 24 out of these 25 genes were also downregulated significantly with
disease. We thus identified 24 genes that were significantly downregulated with disease in each of 5 data
sets (Fig. 1a and Table 1). Box plots of NEUROD6 (Fig. 1b) and SNAP25 (Supplementary Fig. 1) illustrate the consistent downregulation of Table 1 genes across each of the 5 data sets. Additional details on
fold changes and p-values for the 24 genes appear in Supplementary Table 1 (lists of genes differentially
expressed in 4 out of the 5 datasets are also provided, in Supplementary Table 8). While establishing such
a stringent criterion may eliminate some relevant genes, we reasoned that the resulting genes would be
unambiguously associated with AD. The intent of taking the intersection between multiple data sets, each
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Downregulated in AD vs control in all 5 data sets
AP3B2

C14orf132

MRPS11

SLC25A11

ATP1A3

C14orf2

NEUROD6

SNAP25

ATP5B

CACNG3

PPP1R11

SYP

ATP6V1E1

GNG3

PTPRN2

TPI1

ATP6V1G2

GOT2

RGS7

UQCRC1

MAGED1

SLC17A7

YWHAB

BNIP3

Table 1. List of 24 genes downregulated in AD consistently across 5 data sets.

imperfect and bearing its own peculiarities, is to compensate for shortcomings in any single data set.
Indeed, the observed overlap in gene expression effects is striking, especially given that the analysis integrates data across multiple brain compartments and disease timepoints, as well as microarray platforms.
Pathway analysis was performed using DAVID11 on the list of 24 genes. These genes are enriched
significantly in 19 GO CC pathways, including those related to mitochondria, membrane, and vesicles, specifically synaptic vesicle membrane, and 11 GO MF pathways, relating mainly to ATPase activity (Supplementary Table 6). Eight out of the 24 genes are annotated in GO CC as “mitochondrion”
(GO:0005739): ATP5B, ATP6V1E1, BNIP3, C14orf2, GOT2, MRPS11, SLC25A11, and UQCRC1. Several
additional genes are related to mitochondria, as will be discussed below. Four genes are annotated in
GO MF as “ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism”
(GO:0015662): ATP5B, ATP6V1G2, ATP6V1E1, and ATP1A3. Three genes are annotated as “synaptic
vesicle membrane” (GO:0030672): ATP6V1G2, SLC17A7, and SYP. Several genes on the list also have
ties to glutamate (including CACNG3, which regulates AMPA-sensitive glutamate receptors; SLC17A7,
which mediates glutamate uptake into synaptic vesicles; SLC25A11, a mitochondrial oxoglutarate carrier; and GOT2, mitochondrial glutamic-oxaloacetic transaminase 2), which is interesting because both
impairments in glutamatergic transmission and excitotoxicity are thought to play a role in AD12.

Degree of brain-specific expression of identified genes using BioGPS database. To determine
the degree to which these genes were expressed preferentially in the brain, we utilized publicly available
tissue-specific array data, as described in Methods. Overall, for the 24 genes identified, we found a high
degree of specificity for expression in brain tissue (Fig. 1c).
Searching the Gene Expression Omnibus detects gender differences in identified genes. To

generate further insight into the list of expression-identified genes, we developed a method for identifying patterns in the Gene Expression Omnibus (GEO), a large database of publicly available gene expression data sets including over 500,000 human samples. We developed a Wilcoxon-test-based algorithm for
comprehensively searching GEO to identify those samples in which each of the 24 genes was significantly
modulated relative to other genes.
The most striking finding was related to gender, a factor that is suggested to play a role in AD13. As
shown in Supplementary Table 2, the CACNG3, GNG3, and NEUROD6 genes showed a gender-based
pattern. For example, we observed in a dataset from healthy brain, GSE11882 (“Gene expression changes
in the course of normal brain aging are sexually dimorphic”) that 38 samples were significantly enriched
(FDR adjusted p-value <  0.05) for high expression of NEUROD6 (Supplementary Table 3). Strikingly,
30 of the 38 samples with enriched NEUROD6 expression were from males (Fig. 2a). This difference
was highly significant, with hypergeometric p-value 1.71 ×  10−4. In contrast, the entire GSE11882 data
set was well-balanced by gender (173 samples with 82 female and 91 male) (Supplementary Fig. 2). We
analyzed the pattern of NEUROD6 expression across the full data set to search for expression differences
by gender in NEUROD6, and found that NEUROD6 expression was significantly higher in males than
females with a nominal p-value of 0.014 (Fig. 2b). By dividing the data set into individual compartments,
we found that NEUROD6 was significantly differentially expressed in two of the four compartments
(with nominal p-values 0.0052 and 0.007; Supplementary Fig. 3). The finding that NEUROD6 differs in
expression level between healthy men and women is particularly intriguing given that (a) NEUROD6
expression is downregulated with disease, and (b) gender may play a role in AD13.
Examining the GSE11882 data set with regard to the SNAP25 gene, two out of three expression
probesets representing this gene were significantly lower in women than in men, in an individual
compartment in the GSE11882 data set (nominal p-values 0.018 and 0.032; Supplementary Table 4).
Note that GSE11882 was analyzed for differential gene expression between genders, but provided no
Alzheimer-specific information.
To see whether these gender-related differences could have been recovered immediately from the
original gene expression datasets, we also performed differential expression directly on each of these
five AD datasets to examine differences in expression between genders (see Supplementary Table 9). We
were not able to recover differences (beyond nominal p-values) between expression of NEUROD6 and
Scientific Reports | 5:14324 | DOI: 10.1038/srep14324
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Figure 2. Possible link between NEUROD6 and gender. (a) Gender distribution of NEUROD6-high
samples in a data set of healthy controls. (b) Comparison of NEUROD6 expression by gender across the
entire data set of healthy controls.

SNAP25 in males and females in all five datasets (stratified by Alzheimer’s status, see Supplementary
Table 11). In the largest dataset (GSE15222), we observed nominally significant differences in SNAP25
expression between females and males among AD patients but not among controls. In the second largest dataset (GSE44772), SNAP25 differed at least nominally by gender among AD patients and among
controls. In one other dataset, GSE1297, SNAP25 differed at least nominally between M and F among
controls. Fisher’s exact tests comparing the counts of samples originating from males and females, stratifying by disease status, determined that 4 out of the 5 datasets do not show a significant gender bias (see
Supplementary Table 12). These results examining this more subtle effect are not surprising given the
study sizes and different platforms across studies, and underscore the higher sensitivity of the pipeline
described in this work as compared to traditional approaches for analysis.
We chose to focus on NEUROD6 and SNAP25 on the basis of these gender-related patterns and the
genetic analyses described below.

Utilizing SNP studies to identify putatively causative genes. To distinguish between downstream signals resulting from disease pathology, and upstream signals that may be more causative and
therefore better targets for therapy, we utilized single-nucleotide polymorphism (SNP) data in conjunction with the gene expression data. The established method for combining these two types of data,
expression quantitative trait locus (eQTL) analysis14, requires both gene expression and SNP data from
the same cohort of patients. Since most of the available gene expression and SNP data came from separate cohorts, we developed another approach to identify converging lines of evidence for disease-causing
genes from these disparate but complementary types of genomic data.
We examined the regions in and around (details as described below and in Methods) the 24 genes
identified as downregulated in AD (Table 1) for disease-associated SNPs in three data sets: the ADNI1
Scientific Reports | 5:14324 | DOI: 10.1038/srep14324
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cohort, the National Institute on Aging Late-Onset alzheimer’s Disease Family Study (“LOAD study”)15,
and a recent study by Zhang et al. (“Cell study”)3. Limiting the SNPs of interest to targeted regions
reduces the risk of false positives. This narrow focus supports the use of a more lenient p-value threshold greater than the typical threshold applied for GWAS studies (often p <    5 ×  10−8). In order to relax
the threshold from an overly conservative genomewide significance cutoff, yet maintain a desired level
of stringency, we chose to use a p-value threshold of p <  5 ×  10−4. The size of the region surrounding
each gene was taken to be 200 kb up- and downstream, as many enhancer regions for transcriptional
start sites, in general, are known to extend to such distances16. Indeed, in some cases, such elements are
located as far as 1 Mb away from the affected gene; for example, in the case of the genes SHH17 and
POU3F418. For this reason, we performed an additional analysis using less stringent distance and p-value
parameters of 1 Mb and p <  10−2, respectively. For both the strict and less stringent analyses, we defined
a result to be of particular interest if a significant SNP from the GWAS studies comparing AD versus
healthy control was located in the region of one of the AD-downregulated genes, in at least two out of
three SNP studies.
In the case of the least stringent distance and p-value parameters (1 Mb and p <  10−2), for 15 out of
24 genes, significant SNPs were located within the region of interest in all three studies, as shown in
Supplementary Table 7a, and the regions surrounding all but three of the expression-identified genes
contained significant SNPs in at least two out of three studies. For further investigation, we utilized the
results of the stringent filtering (p <  5 ×  10−4, 200 kb; shown in Supplementary Table 7b) to help prioritize genes, as discussed in further detail below.
GWAS studies to date have identified APOE as the gene most consistently associated with AD.
Carriers of the APOE ε 4 (APOE4) allele have a significantly increased risk of AD19 for reasons that
are incompletely understood, and several clinical studies have found putative differences in response to
therapy based on APOE4 status20,21. In addition, recent work suggests that APOE4 imparts an increased
risk of conversion to AD in women22. Given this information as well as the gender differences discussed
above, in addition to examining the regions of interest in all patients, we also performed subset-specific
analyses, based on both gender and apolipoprotein E (APOE) status. We reasoned that different subsets
of AD patients might have differences in the biological factors driving their disease.
SNPs in the region of NEUROD6 were associated with AD specifically in APOE4+ women in both
the ADNI1 and LOAD cohorts (Supplementary Table 7b). These NEUROD6 SNPs are illustrated in
Fig. 3a,c. We utilized a newly developed propensity plotting method to visualize the specific influence
of these SNPs (Fig. 3b,d). Status at these SNPs was highly associated with disease propensity. In contrast, SNPs in the region of SNAP25 were associated with AD specifically in APOE4+ men in both the
LOAD and Cell data sets (Supplementary Table 7b and Supplementary Fig. 4). SNPs were also identified
near MRPS11 for APOE4+ women, and near GOT2 for women as well as for the whole cohort, for the
chosen distance and p-value parameters. We narrowed our focus to NEUROD6 and SNAP25 since their
respective identified SNPs were closer to these genes than to MRPS11 and GOT2, though all of these
genes may have intriguing biological connections, as discussed below.

Identifying medicines to restore expression of causative genes, using CMAP data. We next

sought to determine which medicinal drugs and compounds could restore expression of NEUROD6 or
SNAP25 shown to be downregulated in AD. We developed an enrichment algorithm to identify specific drugs in the Connectivity Map (CMAP)23 databases that induced significantly higher expression of
NEUROD6 or SNAP25 in culture. We identified 34 unique compounds that upregulate NEUROD6, and
nine that upregulate SNAP25 (Table 2). Note that this hypothesis-generating analysis serves to identify
drugs of interest for further examination, and these compounds are not expected to be highly specific for
these genes. The full list of drugs with their known gene/pathway targets is available in Supplementary
Table 10.

Discussion

A number of the genes identified in the expression analysis as downregulated with AD have striking
common biology. The list of 24 genes enriched significantly for GO pathways including those related
to mitochondria, membrane, and vesicles, specifically synaptic vesicle membrane, and ATPase activity
(Supplementary Table 6). Several genes on the list also have ties to glutamate, which is of particular
interest since both impairments in glutamatergic transmission and excitotoxicity are thought to play a
role in AD12. To evaluate which genes on this list were likely to be causal in disease, we examined SNP
data and determined that in particular patient cohorts, significant SNPs were found in multiple data sets
in the regions around NEUROD6 and SNAP25.
NEUROD6 is a transcription factor involved in neuronal differentiation, and has been shown to
increase mitochondrial mass and play a role in response to oxidative stress24. This is intriguing because
the aging process has a negative impact on mitochondrial function25 and leads to an increase in mitochondrial DNA mutations26, and rates of Alzheimer’s increase dramatically with age27.
APOE also has ties to the mitochondria28. The APOE ε 4 isoform has been shown to cause mitochondrial damage specifically in neurons28. APOE ε 4 also has lower antioxidant capability than other isoforms, and amyloid beta induces oxidative stress to a greater extent when APOE ε 4 is present29. Oxidative
stress may also induce hyperphosphorylation of tau30, another key factor in AD. Impairing the transport
Scientific Reports | 5:14324 | DOI: 10.1038/srep14324
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Figure 3. NEUROD6-related SNPs are associated with AD specifically in APOE4+ female patients.
(a) Plot showing a “cone” of disease associated SNPs around NEUROD6 in APOE4+ female patients,
but not in APOE4+ male, APOE4- female, or APOE4- male patients. Top AD-associated SNPs related
to NEUROD6 in APOE4+ female patients in ADNI1 were: rs1917011 (p <  3.82e-5 in female APOE4+
patients, p <  0.692 in male APOE4+ , p <  0.844 in female APOE4-), rs2159766 (p <  3.82e-5 in female
APOE4+ , p <  0.771 in male APOE4+ , p <  0.624 in female APOE4-), and rs12701070 (p <  3.82e-5 in
female APOE4+ , p <  0.561 in male APOE4+ , p <  0.624 in female APOE4-). (b) Propensity plots showing
the disease risk (positive values) or protection (negative values) in APOE4+ female patients as a function
of a patient’s status for each of three top NEUROD6 SNPs. (c) Plot showing disease associated SNP near
NEUROD6 in APOE4+ female patients, but not in APOE4+ male, APOE4- female, or APOE4- male
patients from the LOAD data set. This SNP was rs6972352 (p <  0.00049 in female APOE4+ , p <  0.2247 in
male APOE4+ , and p <  0.010 in female APOE4-). (d) Propensity plots showing the disease risk (positive
values) or protection (negative values) in APOE4+ female patients as a function of a patient’s status for each
of three top NEUROD6 SNPs.

of mitochondria into axons was shown to enhance tau phosphorylation and neurodegeneration31. Several
studies in a variety of systems have shown that oxidative stress induces upregulation of BACE132, an
enzyme critical for the production of amyloid beta. In other systems, oxidative stress has been shown
to increase production of amyloid precursor protein33. Because NEUROD6 confers tolerance to oxidative stress24, it has the potential to mitigate some of this damage. As NEUROD6 expression is lower in
women, and APOE4+ individuals have lowered tolerance for ROS damage28,29, it stands to reason that
a SNP associated with further impairment of NEUROD6 may put APOE4+ females at particular risk of
damage due to oxidative stress.
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CMAP compound name

p.val

adj.p.val

sodium phenylbutyrate

8.03E-05

4.23E-02

arachidonic acid

8.22E-05

4.23E-02

2-deoxy-D-glucose

8.59E-05

4.23E-02

fasudil

8.76E-05

4.23E-02

nordihydroguaiaretic acid

1.04E-04

4.23E-02

monastrol

1.09E-04

4.23E-02

tacrolimus

1.12E-04

4.23E-02

quercetin

1.12E-04

4.23E-02

sulindac

1.14E-04

4.23E-02

troglitazone

1.17E-04

4.23E-02

staurosporine

1.17E-04

4.23E-02

troglitazone

1.22E-04

4.23E-02

thalidomide

1.26E-04

4.23E-02

CP-944629

1.35E-04

4.23E-02

mercaptopurine

1.40E-04

4.23E-02

haloperidol

1.49E-04

4.23E-02

exisulind

1.57E-04

4.23E-02

sirolimus

1.71E-04

4.23E-02

tanespimycin

1.71E-04

4.23E-02

suramin sodium

1.74E-04

4.23E-02

genistein

1.76E-04

4.23E-02

erastin

1.78E-04

4.23E-02

clofibrate

1.80E-04

4.23E-02

LY-294002

1.92E-04

4.23E-02

tanespimycin

1.93E-04

4.23E-02

LY-294002

1.97E-04

4.23E-02

prednisolone

1.99E-04

4.23E-02

fulvestrant

2.01E-04

4.23E-02

meteneprost

2.05E-04

4.23E-02

monorden

2.17E-04

4.23E-02

tretinoin

2.22E-04

4.23E-02

nifedipine

2.30E-04

4.23E-02

sulindac sulfide

2.32E-04

4.23E-02

wortmannin

2.36E-04

4.23E-02

MK-886

2.46E-04

4.29E-02

PF-01378883-00

2.59E-04

4.38E-02

monorden

2.82E-04

4.65E-02

iloprost

3.06E-04

4.91E-02

(A) NEUROD6-elevating compounds

Note: 34 unique compounds. Repeats due to differing cell lines or repeated
experiments.
(B) SNAP25-elevating compounds
valproic acid

2.20E-05

1.91E-02

guanabenz

9.14E-05

3.81E-02

karakoline

8.89E-05

3.81E-02

tetracycline

1.03E-04

4.01E-02

diloxanide

1.28E-04

4.45E-02

metoprolol

1.38E-04

4.52E-02

yohimbic acid

1.59E-04

4.75E-02

azapropazone

1.63E-04

4.75E-02

proguanil

1.93E-04

4.92E-02

Table 2. Drug candidates determined based on patient subset analysis. (a) Compounds that induce
enriched expression of NEUROD6. (b) Compounds that induce enriched expression of SNAP25.
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SNAP25 has an important role in synaptic function as part of the Soluble NSF Attachment Protein
Receptor (SNARE) complex, which is involved in synaptic vesicle exocytosis, and has been tied to neurodegeneration34,35. SNARE proteins are known to be sensitive to oxidative stress, with SNAP25 being
the most sensitive, which has been proposed to relate mitochondrial dysfunction to reduced synaptic
activity in neurodegeneration36. Indeed, in a mouse model of AD using male mice, lower SNAP25 levels
were observed in the hippocampus, along with lowered levels of glutamate, ATP, and mitochondrial
membrane potential; the authors attributed the observed deficiency in glutamatergic neurotransmission
(which requires a high level of energy consumption) to dysfunction of mitochondrial bioenergetics37.
The other two genes identified for the chosen distance and p-value parameters for certain patient
subsets (female APOE4+ , and female as well as whole cohort, respectively) were MRPS11 and GOT2.
Intriguingly, both are mitochondrial genes. MRPS11 encodes a component of the small subunit of
the mitochondrial ribosome. Mutations in other mitochondrial small subunit ribosomal proteins are
known to cause severe disruption in the respiratory chain38. GOT2 encodes a mitochondrial kynurenine
transaminase, which acts on kyurenine to produce kynurenic acid (KYNA), a neuroprotective NMDA
and nicotinic receptor antagonist that may also have antioxidant properties39 and can affect glutamatergic neurotransmission in multiple ways12. Interestingly, lower KYNA levels have been observed in
AD patients40, and raising KYNA levels via inhibition of kyurinine-3-monooxygenase (KMO; another
enzyme that acts on kyurenine) ameliorates neurodegeneration in vivo41.
Several of the compounds identified via our CMAP search as upregulating NEUROD6 or SNAP25
expression have shown promise in published mouse models of AD, as described below. The highest
ranked compound for its ability to upregulate NEUROD6 is sodium phenylbutyrate, which has recently
been proposed as a therapeutic for neurodegenerative diseases due to its ability to increase neurotrophic
factors in brain cells, along with the fact that it is safe, orally delivered, and crosses the blood brain barrier42. Another study using a mouse model of AD demonstrated that independent of Aβ levels, sodium
phenylbutyrate decreased spatial learning and memory impairment by upregulating markers for synapatic and dendritic growth43. The third most highly ranked compound is 2-Deoxy-D-Glucose, which has
been shown to reduce pathology in a female mouse model of AD by inducing ketogenesis and enhancing
mitochondrial capacity44. We propose that these drugs warrant additional investigation as AD therapeutics, particularly in APOE4+ women.
Why is NEUROD6 expression most significant in females? Estrogen signaling appears to stimulate the
production of enzymes such as glutathione peroxidase that protect the mitochondria against oxidative
stress13, so the loss of estrogen upon age could leave women more susceptible to mitochondrial damage
associated with impairment of NEUROD6 production and the resultant loss of protective effects. In fact,
among the list of compounds from CMAP2 that most significantly elevate expression of NEUROD6
(Table 2) is genistein, which has been proposed as a means to replace the protective effect of estrogen
on mitochondria in aging women13.
The top drug shown to significantly elevate SNAP25 expression, valproic acid, is known to have
neuroprotective properties45. In recent studies in mouse models of AD, valproic acid was demonstrated
to protect against loss of neurons46 and limit Aβ production and behavioral deficits47. Karakoline is a
nicotinic receptor agonist that was recently shown to improve cognitive function in a mouse model of
AD48. Tetracycline was shown to protect from Aβ toxicity in C elegans49, and its derivatives are actively
being explored as potential therapeutics in mouse models of AD50. We hypothesize that these compounds
warrant further investigation for treatment of AD, particularly in APOE4+ men.
We developed an innovative pipeline for extracting new insights from existing data sets, utilizing
a breadth of separate, publicly available resources (as illustrated in Fig. 4). This pipeline is innovative
in particular because of the focus on integrating multiple gene expression datasets across various platforms in order to achieve a robust intersection of disease-affected genes, then leveraging these results
in combination with genetic studies in order to identify those that are more likely causal. This approach
has identified NEUROD6 and SNAP25 as important factors in AD, especially in APOE4+ women and
men, respectively. Both of the genes identified have solid connections to the neuronal oxidative damage
response. We have also identified subset-specific drug candidates for modulation of these genes. More
broadly, our analyses suggest that further exploration of gender-specific biology could lead to effective
new medicines for neurodegeneration, along with special considerations for corresponding clinical trials,
and that patient stratification by gender, genetics or other factors could facilitate data-driven identification of new therapeutic options for a variety of diseases.

Methods

Identification, Processing and Analysis of Expression Data Sets.

All expression data sets used
in this analysis were obtained from the Gene Expression Omnibus (GEO) site (http://www.ncbi.nlm.
nih.gov/geo/) and consisted of GEO project accession numbers: GSE528151, GSE129752, GSE3698053,
GSE1522254, and GSE447723. A summary of these data sets, including all sample IDs used in the analysis, array type, and the compartment of the brain that the samples were collected from can be found in
Supplementary Table 5. Each data set was processed and analyzed independently. We identified genes
differentially expressed between AD and control in each using LIMMA (Version 3.18.13)55, taking a
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Figure 4. For legend see next page.
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Figure 4. Schematic of analysis pipeline. (Art credit: Kate Mahan.) We developed an innovative pipeline
for extracting new insights from existing publicly available resources, including five gene expression datasets,
three SNP datasets, and multiple databases, in order to generate hypotheses for potential treatment strategies
in subsets of AD patients. (1) We identified genes differentially expressed in AD in multiple gene expression
data sets, leading to a list of 24 genes downregulated in AD. (2) We searched all of GEO to identify
expression patterns for these genes in additional (not necessarily AD) datasets, revealing gender differences
for some genes. (3) For patient subsets of interest (defined by gender and APOE4 status), we performed
GWAS in each of three separate SNP data sets (AD vs healthy control) in regions up and downstream of 24
genes, allowing prioritization of genes having nearby SNPs. (4) The genes thus identified provide insights
that can help facilitate development of new therapeutics. For example, searching the CMAP database
identified existing drugs warranting further investigation for specific subsets of AD patients. In addition,
further elucidating the biology of these genes can allow identification of entirely new therapeutic targets.

significance threshold of FDR-corrected p-value <  0.05. We further identified the genes significant in
multiple data sets by taking the intersection of the individual differentially expressed gene lists across
studies.
The general analysis method employed for expression data was as follows. CEL files were obtained
from GEO (except where noted) and the data were RMA normalized56. The probesets determined to be
significantly different between the two conditions of interest (in nearly all cases, AD vs control, except
for GSE1297 where this condition was based on low versus high NFT score, as noted below) were calculated using LIMMA. For chips with available MM/PM (mismatch/perfect match) probe data (Affy
U133A or U133 Plus 2.0 chips), results were filtered according to Presence/Absence (P/A) calls computed
in R using the “affy” package57, such that the average P/A call for all of the samples in the condition of
interest with the higher average value (e.g., controls, for probesets downregulated in disease) was at least
marginal.
LIMMA comparisons were used as a metric for assessing the signal to noise tradeoff in each brain
compartment for data sets with multiple brain compartments (visual cortex excluded). The compartment with the greatest number of significant probesets (FDR p-value <  0.05) was chosen for analysis.
For Affymetrix chips, the presence of Affymetrix control probesets among the top significant differential
expression results was considered a QC flag; compartments having Affymetrix control probesets as either
> 0.25% of significant differential expression results, or in any of the top ten results, were discarded.
GSE5281 consists of samples collected from 6 compartments of the brains of AD patients along with
controls and measured using the Affymetrix Human Genome U133 Plus 2.0 Array. We used the samples
collected from the Entorhinal Cortex (EC), per the QC procedure described above.
GSE1297 contains mini-mental state examination (MMSE) scores and neurofibrillary tangle (NFT)
scores for all individuals in the study, with gene expression measurements from the hippocampus made
using the Affymetrix Human Genome U133A Array. We found roughly 5 times as many significant
probesets when comparing the individuals with the 9 highest NFT scores versus the individuals with
the 9 lowest NFT scores than attained when comparing Severe AD patients (based on MMSE score) vs.
controls. For this reason, we used samples with the top 9 NFT scores versus the lowest 9 NFT scores in
this analysis. The lowest 9 NFT scores included both controls and patients labeled as having incipient AD.
The highest 9 NFT scores included patients labeled as having severe AD, moderate AD, and incipient AD.
GSE36980 is comprised of samples from 3 compartments of the brains of AD patients and controls,
measured using the Affymetrix Human Gene 1.0 ST Array. We used the data from the hippocampus as
the compartment with the most probesets significantly differing in expression between AD patients and
controls (as described above).
GSE15222 consists of samples collected from multiple cortical compartments of the brains of AD
patients and controls, measured using the Sentrix HumanRef-8 Expression BeadChip. Raw data was
not available from this data set, so we used the processed data available on the corresponding author’s
laboratory website58. The authors rank-invariant normalized their data and then filtered it in two ways.
First, transcripts were only considered if they were detected in at least 90% of AD patients or 90% of
controls. Second, transcript expression intensities were only considered in analyses for a given sample if
their Illumina detections scores were > 0.9958. Since these data had been normalized across all measured
compartments of the brain, we considered all the samples together.
The net result of these analyses was a list of probesets significantly affected by Alzheimer’s disease
for each data set. To obtain a robust list of affected genes, we determined the intersection of the gene
names from all four lists. We performed separate intersections for genes upregulated in each study and
genes downregulated in each study. After obtaining a list of 25 genes downregulated in disease relative
to control across all four studies, we obtained a fifth data set (GSE44772).
GSE44772, which we obtained after analyzing the other four data sets, consists of samples collected
from three compartments in the brains of both AD patients and controls, measured using a custom
Rosetta/Merck Human 44k 1.1 microarray. Using the same QC procedure described above, we chose
to utilize the data from the prefrontal cortex. Raw data was not available from this data set, so we used
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the processed data available in the Series Matrix File on GEO. The data was in the form of normalized
log10 ratios between the test sample and a pooled reference sample. LIMMA was used to determine
the probesets that were significantly different between the AD patients and the controls. 24 out of the
25 downregulated genes from the four-data set intersection were also significantly downregulated with
disease in this data set.

Brain specificity heat maps. For the 24 genes of interest, all probesets were mapped to tissue-specific

arrays59, available via BioGPS60. The probesets were clustered hierarchically with a metric of Pearson correlation, and displayed via subtracting by the median and dividing by the absolute deviation (both in
GENE-E, http://www.broadinstitute.org/cancer/software/GENE-E/). Tissues were annotated by whether
or not they were brain-associated, and sorted and grouped accordingly.

Stratified GWAS.

We conducted targeted gene association testing from the SNP data sets listed in the
text using PLINK61, with patient subsets defined by gender and APOE4 status. Results were visualized
using the Integrative Genomics Viewer (IGV)62.
In order to obtain the strongest possible AD-relevant signals, we restricted the analysis of the LOAD
data set to only those patients with an AD diagnosis confirmed by autopsy. Similarly, in analysis of the
Zhang et al. data set we excluded controls and patients having a diagnosis of Huntington’s disease.
Of the 757 patients in ADNI1 who were genotyped via Illumina 610 Quad array SNP chip, 389 were
categorized as either AD patients or healthy controls, and the rest (those with mild cognitive impairment,
MCI) were excluded from further consideration. GWAS was also run on patient sub-cohorts, stratified by
APOE4 status, gender, and the combination of both. Effect sizes for each group are as follows: unstratified =  175 AD, 214 healthy controls (HC); APOE4- =  58 AD, 156 HC; APOE4+  =  117 AD, 58 HC;
Female APOE4- =  31 AD, 73 HC; Female APOE4+  =  51 AD, 26 HC; Male APOE4- =  27 AD, 88 HC;
Male APOE4+  =  66 AD, 32 HC; Male all =  93 AD, 115 HC; Female all =  82 AD, 99 HC.
The LOAD data set included 1985 patients and 2058 controls genotyped via Illumina Human 610
Quad v1B SNP chip. Patients included in the analysis were limited to those who had an AD diagnosis
confirmed by autopsy. Unstratified, subjects included in the analysis were 440 patients and 2058 controls. Numbers of subjects within subsets were: APOE4- =  99 AD, 1256 HC; APOE4+  =  341 AD, 802
HC; Female APOE4- =  74 AD, 773 HC; Female APOE4+  =  230 AD, 483 HC; Male APOE4- =  25 AD,
483 HC; Male APOE4+  =  111 AD, 319 HC; Male all =  136 AD, 802 HC; Female all =  304 AD, 1256 HC.
The Zhang et al. (or “CELL”) data set included 374 patients and 366 controls genotyped via Illumina
HumanHap650Y SNP chip. We excluded subjects with a diagnosis of Huntington’s disease from the
analysis. Unstratified, 371 patients and 159 controls were included in the analysis. Numbers of subjects in
subsets were as follows: APOE4- =  209 AD, 130 HC; APOE4+  =  162 AD, 29 HC; Female APOE4- =  129
AD, 34 HC; Female APOE4+  =  90 AD, 5 HC; Male APOE4- =  80 AD, 96 HC; Male APOE4+  =  72 AD,
24 HC; Male all =  152 AD, 120 HC; Female all =  219 AD, 39 HC. In this data set we removed from
consideration patients and controls with a diagnosis of Huntington’s disease. Therefore, smaller numbers
of controls were available, especially in the highly stratified subsets. Specifically, the female APOE+
cohort contained only five controls, which may explain why SNPs calculated to be significant in female
APOE4+ patients in the other two data sets did not achieve significance in this subset.

Propensity plotting. We adapt a measure of bias for identifying amino acids on the surface that are
likely to be part of an interface domain from the proteomics field63–65 to measure the preference of a
particular SNP genotype to case vs. control subsets of the data set. Briefly, we define SNP propensity to
be the fraction of patients diagnosed with AD given a particular SNP variant to the control fraction with
this SNP variant. Specifically, it is defined as:
log 2 (PropensityrsX = i ) =

CASE_i
CASE
CASE i + CONTROL_i
CASE + CONTROL

(1)

Where CASEi is the fraction of patients diagnosed with AD and having SNP variant i. CONTROLi is the
fraction of control individuals with SNP variant i. CASE is the total number of patients diagnosed with
AD in the data set, and CONTROL is the total number of control individuals in the data set.

GEO-search analysis. We searched all human data sets across all platforms in GEO as of July 2013.
We used a one-sample Wilcoxon test to measure the significance of differential expression for probesets annotated to a gene of interest against all other probesets in the sample, correcting for FDR using
Benjamini-Hochberg.
Supplementary Table 2 was constructed by counting the number of samples, m, from the GSE11882
data set that passed our adjusted p-value threshold of 0.05 for the GEO search algorithm described
above. Of the samples that passed our adjusted threshold of 0.05, we counted the number of samples,
n, that came from males. We then calculated the significance of obtaining ≥  n male samples if we drew
m samples randomly from a total of 173 samples (which is the total number of samples in GSE11882)
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with 91 males (total number of male samples in GSE11882) based on the hypergeometric distribution.
We omitted the significance calculation if the number of significant samples, m, was less than 15 (< 10%
of the data set).

CMAP search. CMAP (Connectivity Map) is a large collection of microarray-based transcriptional
signatures for 7000 expression profiles from cultured cells treated with 1,309 compounds. We obtained
the full CMAP (builds 01 and 02)66,23 data sets and utilized a one-sample Wilcoxon test to identify
expression profiles from compounds that significantly increased expression of a gene of interest in culture
after treatment. We then adjusted for multiple hypothesis testing (FDR p-value <  0.05).
ADNI-data acquisition. The SNP data used in the preparation of this article were obtained from

the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI was
launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public- private partnership. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease
(AD). Determination of sensitive and specific markers of very early AD progression is intended to aid
researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen
the time and cost of clinical trials. The Principal Investigator of this initiative is Michael W. Weiner, MD,
VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many
co- investigators from a broad range of academic institutions and private corporations, and subjects have
been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit
800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols
have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively
normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally
recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see www.adni-info.org.
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